Kineta Inc. buy melinda
Start price
22.09.17
/
50%
€252.56
Target price
30.11.17
€631.40
Performance (%)
30.00%
End price
30.11.17
€328.33
Summary
This prediction ended on 30.11.17 with a price of €328.33. The prediction had a final performance of 30.00%. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Kineta Inc. | 4.950% | 4.950% | -86.182% | -99.364% |
| iShares Core DAX® | 3.178% | 0.980% | 15.331% | 18.044% |
| iShares Nasdaq 100 | 2.972% | 0.925% | 39.831% | 50.841% |
| iShares Nikkei 225® | 0.545% | -4.556% | 17.661% | 3.434% |
| iShares S&P 500 | 2.367% | 0.833% | 30.000% | 44.095% |
Comments by melinda for this prediction
In the thread Proteostasis Therapeutics Inc diskutieren
Biotechnologie und medizinische SecteurRecherche
Proteostase Therapeutics, Inc. engagiert in der Forschung, Entwicklung und Vermarktung von Arzneimitteln. Seine Medikamente beabsichtigen Mukoviszidose, die Proteinkonformation und neurodegenerative Erkrankungen zu behandeln. Das Unternehmen wurde von William Balch, Jeffery Kelly, Andrew Dillin, Richard gegründet